Parameter
| Biomarker | BRAF V600E Mut | Full name | BRAF V600E Mutation | Molecular Type | Gene Mutation |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prediction |
| Disease | Glioblastoma | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue/Plasma (NGS, ARMS-PCR) | ||
| Pathobiological Mechanisms | Activates the MAPK/ERK signaling pathway, driving tumor cell proliferation and angiogenesis. | ||||
| Clinical Availability Status | Under clinical validation | ||||
| Notes and Dynamics | Dabrafenib combined with trametinib (BRAF+MEK inhibitors) has an objective response rate of 27% in GBM patients with BRAF V600E mutation in clinical trials. | ||||